GXO Logistics Inc vs Eli Lilly And Co — how do they compare? GXO Logistics Inc trades at $54.2 (market cap $6.02B), while Eli Lilly And Co trades at $1,170.97 (market cap $1.03T). The key difference: Eli Lilly And Co is far larger — about 171.1× GXO Logistics Inc's market cap, and Eli Lilly And Co pays a 0.6% dividend while GXO Logistics Inc pays none. Which is the better fit depends on your goals.
| GXO | LLY | |
|---|---|---|
Market Cap | $6.02B | $1.03T |
Sector | Industrials | Health |
52-Week High | $65.59 | $1.24K |
52-Week Low | $45.52 | $625.65 |
Enterprise Value | $11.18B | $1.07T |
Dividend Yield | — | 0.6% |
Signals from Pluang's Aura AI — not financial advice
GXO Logistics is trading at $53.36, up 7.43% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamental performance with three consecutive quarterly earnings beats and 10.8% revenue growth in Q1 2026. Analyst sentiment remains overwhelmingly positive with 16 buy ratings and a $66.60 consensus price target representing 25% upside potential. Recent business developments include multiple partnership renewals and expansion into strategic verticals like aerospace and defense.
GXO presents a compelling investment opportunity with strong earnings momentum and institutional support, though investors should monitor competitive pressures from Amazon's logistics expansion and the company's transition toward higher-margin verticals. The stock's current valuation at 46.69x P/E appears elevated relative to modest net margins, requiring continued execution on growth initiatives to justify premium multiples.
Eli Lilly (LLY) trades at $1,176.75, up 1.95% on the day, with strong fundamentals including a 31.66% net margin and consistent earnings beats. The stock shows a bearish technical signal near resistance at $1,177, while recent news highlights the $2.8 billion acquisition of AtaiBeckley to expand its mental health pipeline. Operating cash flow surged to $16.81 billion in 2025, supporting growth initiatives in obesity and Alzheimer's treatments.
Outlook remains positive with a $1.38K analyst price target and 73% buy ratings, but risks include competitive pressure in obesity drugs and high valuation multiples. Revenue growth of 65% in 2025 underscores momentum, though debt levels and acquisition integration pose challenges for sustained outperformance.
Trailing returns across standard periods
Latest headlines on both assets
GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.
Read more on GXO →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →